Metaderm Eczema And Baby Eczema Cream

Achillea Millefolium, Aesculus Hippocastanum, Berberis Vulgaris, Conium Maculatum, Matricaria Chamomilla, Phytolacca Decandra, Rhus Toxicodendron, Sanguinaria Canadensis


Cosmetic Specialty Labs, Inc.
Human Otc Drug
NDC 58133-360
Metaderm Eczema And Baby Eczema Cream also known as Achillea Millefolium, Aesculus Hippocastanum, Berberis Vulgaris, Conium Maculatum, Matricaria Chamomilla, Phytolacca Decandra, Rhus Toxicodendron, Sanguinaria Canadensis is a human otc drug labeled by 'Cosmetic Specialty Labs, Inc.'. National Drug Code (NDC) number for Metaderm Eczema And Baby Eczema Cream is 58133-360. This drug is available in dosage form of Cream. The names of the active, medicinal ingredients in Metaderm Eczema And Baby Eczema Cream drug includes Achillea Millefolium - 4 [hp_M]/mL Aesculus Hippocastanum Seed Oil - 4 [hp_M]/mL Berberis Vulgaris Fruit - 9 [hp_M]/mL Conium Maculatum Fruit - 21 [hp_M]/mL Matricaria Chamomilla Flowering Top Oil - 5 [hp_M]/mL Phytolacca Octandra Leaf - 11 [hp_M]/mL Rhus Spp. Whole - 13 [hp_M]/mL Sanguinaria Canadensis Root - 8 [hp_M]/mL . The currest status of Metaderm Eczema And Baby Eczema Cream drug is Active.

Drug Information:

Drug NDC: 58133-360
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Metaderm Eczema And Baby Eczema Cream
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Achillea Millefolium, Aesculus Hippocastanum, Berberis Vulgaris, Conium Maculatum, Matricaria Chamomilla, Phytolacca Decandra, Rhus Toxicodendron, Sanguinaria Canadensis
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Cosmetic Specialty Labs, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Cream
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:ACHILLEA MILLEFOLIUM - 4 [hp_M]/mL
AESCULUS HIPPOCASTANUM SEED OIL - 4 [hp_M]/mL
BERBERIS VULGARIS FRUIT - 9 [hp_M]/mL
CONIUM MACULATUM FRUIT - 21 [hp_M]/mL
MATRICARIA CHAMOMILLA FLOWERING TOP OIL - 5 [hp_M]/mL
PHYTOLACCA OCTANDRA LEAF - 11 [hp_M]/mL
RHUS SPP. WHOLE - 13 [hp_M]/mL
SANGUINARIA CANADENSIS ROOT - 8 [hp_M]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:TOPICAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 15 Aug, 2018
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 24 Dec, 2025
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:Cosmetic Specialty Labs, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UPC:0726670462909
0726670462824
UPC stands for Universal Product Code.
UNII:2FXJ6SW4PK
E0M52HIR1Y
6XEF22AHC3
Y71WKJ3A2K
SA8AR2W4ER
0804KD28Q9
3U7FG9T9MW
N9288CD508
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
58133-360-06193 mL in 1 BOTTLE (58133-360-06)15 Aug, 2018N/ANo
58133-360-32950 mL in 1 BOTTLE (58133-360-32)15 Aug, 2018N/ANo
58133-360-65193 mL in 1 BOTTLE (58133-360-65)15 Aug, 2018N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Purpose eczema relief *the letters h.p.u.s. indicate that the components in this product are officially monographed in the homeopathic pharmacopoeia of the united states.

Product Elements:

Metaderm eczema and baby eczema cream achillea millefolium, aesculus hippocastanum, berberis vulgaris, conium maculatum, matricaria chamomilla, phytolacca decandra, rhus toxicodendron, sanguinaria canadensis carthamus tinctorius (safflower) oleosomes veronica officinalis leaf althaea officinalis leaf scrophularia nodosa matricaria chamomilla flowering top oil matricaria chamomilla flowering top oil sanguinaria canadensis root sanguinaria canadensis root achillea millefolium achillea millefolium berberis vulgaris fruit berberis vulgaris fruit conium maculatum fruit conium maculatum fruit water alpha-tocopherol acetate triethanolamine laurylaminopropionate aloe vera leaf cetyl alcohol hamamelis virginiana root bark/stem bark phenoxyethanol caprylyl glycol carbomer 940 dimethicone hydrastis canadensis whole lens culinaris fruit sambucus nigra flower oil malva sylvestris leaf tussilago farfara rhus spp. whole rhus spp. whole phytolacca octandra leaf phytolacca octandra leaf stearic acid niacinamide sodium pyrrolidone carboxylate pyrrolidone carboxylic acid avena sativa leaf populus tremuloides leaf populus alba leaf cochlearia officinalis leaf aesculus hippocastanum seed oil aesculus hippocastanum seed oil sarsaparilla nasturtium officinale vincetoxicum atratum root pimpinella saxifraga root glyceryl stearate se petrolatum

Indications and Usage:

Uses: temporarily relieves the dryness, itching, flaking, rash, redness, and skin irritation associated with eczema.

Warnings:

Warnings: for external use only

When Using:

When using this product: avoid contact with eyes. if swallowed, get medical help or contact a poison control center immediately. test for allergy by rubbing small amount on skin first. do not use if allergic to or hypersensitive to any ingredient. if condition worsens or does not improve consult a doctor.

Dosage and Administration:

Directions: apply to affected area 2 times daily or as needed.

Stop Use:

Stop use and ask a doctor if: condition worsens symptoms persist for more than 7 days or clear up and occur again within a few days redness is present irritation develops

Package Label Principal Display Panel:

Principal display panel and drug facts df2 pdp2 df1 pdp1


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.